12,000 koreans monitored for vaccine side effects over 6 years
NCT ID NCT05032976
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is monitoring the safety of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in 12,000 people in South Korea who received the vaccine as part of routine care. Researchers are tracking side effects like sore arms or fever within a week of each dose, as well as any other health issues that arise within a month. The goal is to gather real-world safety data from 2021 to 2027 to ensure the vaccine remains safe for the public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BNT162b2 (Pfizer-BioNTech COVID-19 vaccine)
What this could lead to
If successful, this study will provide real-world safety data on the BNT162b2 vaccine in a large Korean population, helping confirm its safety profile.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors and may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea